Menu
Start Screening

Frontier mental health research: psychedelics & drug studies

Each month our editorial team sifts through hundreds of papers and curates notable findings—for practitioners and informed readers who want to stay current with the evidence. Subscribe to the monthly Research Digest for expert analysis and concise summaries of key papers.

Ayahuasca Sadness or low mood Depression (economics)

1 paper

Ayahuasca for Sadness or low mood

Based on 15 papers

Research on ayahuasca for sadness and low mood shows promise but is still early. Lab and animal studies suggest its active ingredient, DMT, can change brain connections. Small human trials and patient reports find mood improvements for some people, especially in hard-to-treat depression. However, most clinical studies are small or preliminary. Safety, who the results apply to, and exactly how the brew helps are not settled. Scientists say more large, careful trials with diverse participants and good medical oversight are needed.

Key findings

  • Ayahuasca is a traditional plant brew. One plant provides DMT and the other has chemicals that stop the body from breaking DMT, so the DMT works when you drink it (not just when injected or smoked). 15082 15059
  • In lab and animal studies, DMT and related compounds can make neurons grow new branches and form more connections, which could help change mood. But some animal studies found different effects depending on dose or sex, so results are not uniform. 15050 15082
  • Small clinical studies and early human trials report reductions in depression symptoms after ayahuasca or DMT treatments, with the strongest and most consistent promise for treatment‑resistant major depression so far. 15082 15060 15063
  • Overall evidence in humans is still limited. Many trials are small or early‑stage, so researchers say larger and better‑controlled studies are needed before firm conclusions can be drawn. 15082 15063 15085
  • Patients often describe helpful psychological processes such as personal insight, a changed sense of self, and feeling more connected to others. These kinds of experiences — plus preparation and therapy before and after the session — are strongly linked to better outcomes. 15092 15063 15091
  • Safety matters. Reviews and experts stress the need for medical oversight, careful set and setting, and follow‑up care. The growing psychedelic industry also raises ethical and legal questions that affect how treatments are delivered. 15091 15085 15082
  • A large review of many psychoplastogen studies found no clear rise in blood levels of BDNF (a protein sometimes linked to brain change) after these drugs. That suggests blood BDNF may not be a reliable marker of how these drugs affect the human brain. 15129
  • Most past psychedelic therapy studies included mostly White participants. Because ayahuasca comes from Indigenous traditions and people of color were underrepresented in research, study results may not apply to all cultural or ethnic groups. 15095 15058 15082

Ayahuasca and Its Main Component N,N-Dimethyltryptamine (DMT) for the Treatment of Mental Disorders: Mechanisms of Action, Clinical Studies, and Tools to Explore the Human Mind

Alice Melani, Giorgia Papini, Marco Bonaso, Letizia Biso, Shivakumar Kolachalam, Nicola Luigi Bragazzi, et al.
Biomedicines Summary & key facts 2026 0 citations

This paper reviews research on ayahuasca and its main ingredient, DMT, and how they might help with mental health. Ayahuasca is a plant brew that makes DMT work when you drink it because it also contains chemicals that stop the body from breaking DMT down. Lab studies and a small…

Alkaloids: synthesis and pharmacology Forensic Toxicology and Drug Analysis Psychedelics and Drug Studies Ayahuasca MDMA
Summaries and links are for general information and education only. They are not a substitute for reading the original publication or for professional medical, legal, or other advice. Always refer to the linked source for the full study.